There’s also a healthy dose of L-Carnitine, Choline, and L-Glutamine, to support in burning fat, enhancing focus, and building muscle. Turn your reserves into usable energy! Once you’ve tried it, it’s gonna be a case of “LXR forever!” Westerterp, M. et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 25, 1294–1304 e1296 (2017). Holze, C. et al. Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway. Nat. Immunol. 19, 130–140 (2018).

Terasaka, N. et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6–11 (2003). Ghisletti, S. et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 23, 681–693 (2009). Kennedy, M. A. et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1, 121–131 (2005).Tamura, K. et al. LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc. Natl Acad. Sci. USA 97, 8513–8518 (2000). King, A. J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100–11105 (2006). Janowski, B. A. et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl Acad. Sci. USA 96, 266–271 (1999). Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193–202 (2020).

Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors, RXR, and the big bang. Cell 157, 255–266 (2014). Brunham, L. R. et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116, 1052–1062 (2006).Hannah, V. C., Ou, J., Luong, A., Goldstein, J. L. & Brown, M. S. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J. Biol. Chem. 276, 4365–4372 (2001). Tian, J., Goldstein, J. L. & Brown, M. S. Insulin induction of SREBP-1c in rodent liver requires LXRalpha-C/EBPbeta complex. Proc. Natl Acad. Sci. USA 113, 8182–8187 (2016). a, Analysing potential liver damage in C57BL/6 wildtype mice upon a 3-week T0901317/sorafenib treatment. b, Liver-to-body ratio of mice upon a 3-week treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 3 mice per group, statistical significance was calculated using two-tailed Student´s t test). c, Representative pictures of murine livers upon a 3-week treatment with T0901317/sorafenib or carrier that were stained with H+E, Oil red O, Ki67, cleaved caspase 3, TUNEL and Sirius red ( n = 3 mice per group). TUNEL and cleaved caspase 3 positive control = Intraperitoneal injection of Jo2 antibody. Sirius red positive control = Bi-weekly intraperitoneal injections of CCl 4 for 6 weeks. Ki67 positive control = Myc OE; Nras G12V HCC. Scale bars, 100 µm. d, Analysing potential liver damage in C57BL/6 wildtype mice upon 6 months of T0901317/sorafenib treatment. e, Liver-to-body ratio of mice upon a 6-month treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 6 mice per group, statistical significance was calculated using two-tailed Student´s t test). f, Representative pictures of murine livers upon a 6-month treatment with T0901317/sorafenib or carrier that were stained with H + E, Oil red O, Ki67, cleaved caspase 3, TUNEL and Sirius red ( n = 6 mice per group). Scale bars, 100 µm. g,h, Weight development of mice during 2 weeks ( g) or 6 months ( h) of treatment with T0901317/sorafenib or carrier (values represent mean ± SD, n = 3 (g) or 6 (h) mice per group, statistical significance was calculated using two-tailed Student´s t test). Numerical source data are provided as source data files.